Optimal  ||| S:0 E:8 ||| JJ
management  ||| S:8 E:19 ||| NN
of  ||| S:19 E:22 ||| IN
recurrent  ||| S:22 E:32 ||| JJ
ovarian  ||| S:32 E:40 ||| JJ
cancer  ||| S:40 E:47 ||| NN
The  ||| S:47 E:51 ||| DT
development  ||| S:51 E:63 ||| NN
of  ||| S:63 E:66 ||| IN
an  ||| S:66 E:69 ||| DT
optimal  ||| S:69 E:77 ||| JJ
management  ||| S:77 E:88 ||| NN
approach  ||| S:88 E:97 ||| NN
in  ||| S:97 E:100 ||| IN
recurrent  ||| S:100 E:110 ||| JJ
ovarian  ||| S:110 E:118 ||| JJ
cancer  ||| S:118 E:125 ||| NN
requires  ||| S:125 E:134 ||| VBZ
careful  ||| S:134 E:142 ||| JJ
consideration  ||| S:142 E:156 ||| NN
of  ||| S:156 E:159 ||| IN
a  ||| S:159 E:161 ||| DT
number  ||| S:161 E:168 ||| NN
of  ||| S:168 E:171 ||| IN
important  ||| S:171 E:181 ||| JJ
factors  ||| S:181 E:189 ||| NNS
including  ||| S:189 E:199 ||| VBG
( ||| S:199 E:200 ||| -LRB-
a ||| S:200 E:201 ||| LS
)  ||| S:201 E:203 ||| -RRB-
response  ||| S:203 E:212 ||| NN
to  ||| S:212 E:215 ||| TO
and  ||| S:215 E:219 ||| CC
severity ||| S:219 E:227 ||| CD
/ ||| S:227 E:228 ||| CD
persistence  ||| S:228 E:240 ||| NN
of  ||| S:240 E:243 ||| IN
toxicity  ||| S:243 E:252 ||| VBG
associated  ||| S:252 E:263 ||| VBN
with  ||| S:263 E:268 ||| IN
prior  ||| S:268 E:274 ||| JJ
therapy ||| S:274 E:281 ||| NN
,  ||| S:281 E:283 ||| ,
( ||| S:283 E:284 ||| -LRB-
b ||| S:284 E:285 ||| LS
)  ||| S:285 E:287 ||| -RRB-
existence  ||| S:287 E:297 ||| NN
of  ||| S:297 E:300 ||| IN
relevant  ||| S:300 E:309 ||| JJ
trial  ||| S:309 E:315 ||| NN
data  ||| S:315 E:320 ||| NNS
( ||| S:320 E:321 ||| -LRB-
particularly  ||| S:321 E:334 ||| RB
phase  ||| S:334 E:340 ||| VB
3  ||| S:340 E:342 ||| CD
studies ||| S:342 E:349 ||| NNS
) ||| S:349 E:350 ||| -RRB-
,  ||| S:350 E:352 ||| ,
( ||| S:352 E:353 ||| -LRB-
c ||| S:353 E:354 ||| LS
)  ||| S:354 E:356 ||| -RRB-
patient  ||| S:356 E:364 ||| JJ
interest  ||| S:364 E:373 ||| NN
in  ||| S:373 E:376 ||| IN
participating  ||| S:376 E:390 ||| VBG
in  ||| S:390 E:393 ||| IN
clinical  ||| S:393 E:402 ||| JJ
trials ||| S:402 E:408 ||| NNS
,  ||| S:408 E:410 ||| ,
( ||| S:410 E:411 ||| -LRB-
d ||| S:411 E:412 ||| LS
)  ||| S:412 E:414 ||| -RRB-
cost  ||| S:414 E:419 ||| NN
of  ||| S:419 E:422 ||| IN
( ||| S:422 E:423 ||| -LRB-
and  ||| S:423 E:427 ||| CC
ability  ||| S:427 E:435 ||| NN
to  ||| S:435 E:438 ||| TO
pay  ||| S:438 E:442 ||| VB
for ||| S:442 E:445 ||| IN
)  ||| S:445 E:447 ||| -RRB-
particular  ||| S:447 E:458 ||| JJ
anti-neoplastic  ||| S:458 E:474 ||| JJ
drug  ||| S:474 E:479 ||| NN
regimens ||| S:479 E:487 ||| NN
,  ||| S:487 E:489 ||| ,
and  ||| S:489 E:493 ||| CC
( ||| S:493 E:494 ||| -LRB-
e ||| S:494 E:495 ||| LS
)  ||| S:495 E:497 ||| -RRB-
patient  ||| S:497 E:505 ||| JJ
choice ||| S:505 E:511 ||| NN
.  ||| S:511 E:513 ||| .
It  ||| S:513 E:516 ||| PRP
is  ||| S:516 E:519 ||| VBZ
likely  ||| S:519 E:526 ||| RB
that  ||| S:526 E:531 ||| IN
the  ||| S:531 E:535 ||| DT
increasing  ||| S:535 E:546 ||| JJ
availability  ||| S:546 E:559 ||| NN
of  ||| S:559 E:562 ||| IN
biologically  ||| S:562 E:575 ||| JJ
active  ||| S:575 E:582 ||| JJ
novel  ||| S:582 E:588 ||| NN
agents  ||| S:588 E:595 ||| NNS
( ||| S:595 E:596 ||| -LRB-
and  ||| S:596 E:600 ||| CC
combination  ||| S:600 E:612 ||| NN
programs ||| S:612 E:620 ||| NNS
)  ||| S:620 E:622 ||| -RRB-
in  ||| S:622 E:625 ||| IN
this  ||| S:625 E:630 ||| DT
clinical  ||| S:630 E:639 ||| JJ
setting  ||| S:639 E:647 ||| NN
will  ||| S:647 E:652 ||| MD
add  ||| S:652 E:656 ||| VB
to  ||| S:656 E:659 ||| TO
the  ||| S:659 E:663 ||| DT
difficulty  ||| S:663 E:674 ||| NN
of  ||| S:674 E:677 ||| IN
defining  ||| S:677 E:686 ||| FW
optimal  ||| S:686 E:694 ||| FW
therapy  ||| S:694 E:702 ||| FW
in  ||| S:702 E:705 ||| FW
recurrent ||| S:705 E:714 ||| FW
/ ||| S:714 E:715 ||| FW
resistant  ||| S:715 E:725 ||| FW
ovarian  ||| S:725 E:733 ||| FW
cancer ||| S:733 E:739 ||| NN
,  ||| S:739 E:741 ||| ,
which ||| S:741 E:746 ||| WDT
,  ||| S:746 E:748 ||| ,
in  ||| S:748 E:751 ||| IN
many  ||| S:751 E:756 ||| JJ
individuals ||| S:756 E:767 ||| NNS
,  ||| S:767 E:769 ||| ,
can  ||| S:769 E:773 ||| MD
be  ||| S:773 E:776 ||| VB
reasonably  ||| S:776 E:787 ||| RB
considered  ||| S:787 E:798 ||| VBN
a  ||| S:798 E:800 ||| DT
very  ||| S:800 E:805 ||| RB
serious  ||| S:805 E:813 ||| JJ
chronic  ||| S:813 E:821 ||| JJ
disease  ||| S:821 E:829 ||| NN
process ||| S:829 E:836 ||| NN
.  ||| S:836 E:838 ||| .
